Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr Daver on the Initial Safety of DSP-5336 in Relapsed/Refractory Acute Leukemia

July 1st 2024

Naval G. Daver, MD, discusses updated findings from a phase 1/2 study of the menin-MLL inhibitor DSP-5336 in relapsed/refractory acute leukemias.

DREAMM-7 Update: Subgroup Analyses From a Phase 3 Trial of Belantamab Mafodotin (Belamaf) + Bortezomib and Dexamethasone (BVd) vs Daratumumab, Bortezomib, and Dexamethasone (DVd) in Relapsed/Refractory Multiple Myeloma (RRMM)

June 28th 2024

DREAMM-7 (NCT04246047) is a global, randomized, open-label, phase III head-to-head trial evaluating the efficacy and safety of BVd triplet vs SoC triplet, DVd, in patients (pts) with RRMM with ≥1 prior line of therapy.

Dr Maakaron on Choosing Between Bispecific Antibodies and CAR T-Cell Therapy in DLBCL

June 27th 2024

Joseph Maakaron, MD, discusses factors that influence his decision to use bispecific antibodies or CAR T-cell therapy in patients with DLBCL.

FDA Modifies REMS for Autologous CAR T-Cell Therapies in Hematologic Malignancies

June 27th 2024

The FDA has modified the risk evaluation and mitigation strategies for CAR T-cell therapies approved for hematologic malignancies.

Liso-cel Shows Improved EFS, PFS, and Durable Responses in Second-line LBCL at 3 Years

June 27th 2024

Liso-cel continued to show improved disease control and EFS and PFS vs SOC in the second-line treatment of patients with large B-cell lymphoma.

Dr Hu on Choosing Between Bispecific Antibodies vs CAR T-Cell Therapy in DLBCL

June 27th 2024

Marie Hu, MD, discusses her decision-making process when considering bispecific antibodies vs CAR T-cell therapy in patients with DLBCL.

FDA Grants Accelerated Approval to Epcoritamab for Relapsed/Refractory Follicular Lymphoma

June 26th 2024

The FDA has granted accelerated approval to epcoritamab-bysp (Epkinly) for the treatment of adult patients with relapsed or refractory follicular lymphoma following 2 or more lines of systemic therapy.

Dr Erba on the Safety of Quizartinib By Treatment Phase and Age in FLT3-ITD–positive AML

June 25th 2024

Harry Erba, MD, PhD, discusses the safety profile of quizartinib according to treatment phase and age in newly diagnosed patients with FLT3-ITD–positive acute myeloid leukemia.

Dr Bansal on Outpatient Administration With Axi-Cel and Brexu-Cel in R/R NHL

June 25th 2024

Radhika Bansal, MBBS, discusses outpatient administration of axi-cel and brexu-cel in relapsed/refractory non-Hodgkin lymphoma.

Phase 3 Study Results of Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Versus VRd for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma (IMROZ)

June 25th 2024

IMROZ (NCT03319667) is the first global Phase 3 study of an anti-CD38 mAb in combination with VRd in patients with transplant-ineligible NDMM.

Dr Winter on Unmet Needs in Richter Transformation for Patients With CLL

June 24th 2024

Allison Winter, MD, discusses unmet needs for patients with Richter transformation from CLL.

Dr Ip on the Impact of BCMA Alternative Splicing in Lymphoma and Multiple Myeloma

June 24th 2024

Andrew Ip, MD, discusses alternative splicing of the TNFRSF17 gene, which encodes BCMA, in patients with lymphoma or multiple myeloma.

FDA Approves Crovalimab for Paroxysmal Nocturnal Hemoglobinuria

June 24th 2024

The FDA has approved crovalimab for patients 13 years of age and older with paroxysmal nocturnal hemoglobinuria and a body weight of at least 40 kg.

Dr Winer on the Rationale for the TakeAim Leukemia Trial in Mutated AML

June 21st 2024

Eric Winer, MD, discusses the rationale for the phase 1/2a TakeAim Leukemia trial of emavusertib in patients with R/R FLT3- and spliceosome-mutated AML.

Dr Al Malki on Outcomes With PTCy-Based GVHD Prophylaxis in Hematologic Malignancies

June 21st 2024

Monzr M. Al Malki, MD, discusses outcomes with mismatched unrelated donor transplantation using post-transplant cyclophosphamide–based GVHD prophylaxis.

Ongoing Research Efforts and More in Ph+ Acute Lymphoblastic Leukemia

June 21st 2024

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss ongoing research efforts in the treatment paradigm of Philadelphia chromosome–positive acute lymphoblastic leukemia.

Dr Jimenez Jimenez on PBSC from HLA-Mismatched Donors in Hematological Malignancies

June 21st 2024

Antonio Martin Jimenez Jimenez, MD, discusses conditioning therapy, PBSC from HLA-MMUD, and PTCy for GVHD prophylaxis in hematological malignancies.

Safety Data With Ponatinib in PHALLCON for Ph+ Acute Lymphoblastic Leukemia

June 21st 2024

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss safety findings from the PHALLCON trial of ponatinib in Philadelphia chromosome–positive acute lymphoblastic leukemia.

Clinical Efficacy With Ponatinib in the PHALLCON Trial for Ph+ ALL

June 21st 2024

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss the efficacy with ponatinib observed in the PHALLCON trial of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

The Impact of the Ponatinib FDA Approval in Newly Diagnosed Ph+ ALL

June 21st 2024

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss the impact of the FDA approval of ponatinib for the treatment of newly diagnosed patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.